CRO gets NCI grant to boost cancer trial recruitment

- Last updated on GMT

The US National Cancer Institute (NCI) will provide specialist trial group Cancer Research for the Ozarks (CRO) with a $4.2m grant to support its clinical programme.

The funding, which will be rolled out over a five year period, is designed to improve CRO’s ability to match suitable cancer patients with trial programmes being run by key collaborators like the Cox Health and St John’s hospital groups.

The grant, which is equivalent to 80 per cent of the funding required by CRO, will be supported by contributions from both Cox Health and St John’s

CRO’s director Marilyn Bauer told New-Leader.com that: “We’re pleased that in a time when a lot of people aren't getting funded, we did. And that really speaks to the quality of our program.”

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers